文献速递血栓与止血

αIIbβ3拮抗剂可在不引起Fc受体γ链IIa介导的血小板减少的情况下预防血栓形成

An αIIb β3 antagonist prevents thrombosis without causing Fc receptor γ-chain IIa-mediated thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2017-10-09

研究探讨αIIbβ3结合表位与药物依赖性抗体(DDAb)诱导的关系,利用FcγRIIa转基因小鼠比较两种解整合素TMV-2与TMV-7。TMV-7识别αIIbβ3的β螺旋桨结构域,不引起构象改变及FcγRIIa介导的血小板减少,且不损害止血能力,而依替巴肽和TMV-2则引起严重血小板减少并延长出血时间。

要点

  • TMV-7识别αIIbβ3的β螺旋桨结构域,不诱导αIIbβ3构象改变。
  • TMV-7与AP2共处理不引起FcγRIIa介导的血小板聚集及下游活化级联。
  • TMV-7有效预防体内闭塞性血栓且不损害止血能力。

核心结论

  • TMV-7通过不同于其他受试αIIbβ3拮抗剂的机制发挥抗血小板和抗血栓活性,可能作为具有更好安全性的治疗药物提供优势。

研究设计与样本

  • 在FcγRIIa转基因小鼠中,研究TMV-2和TMV-7在AP2(一种抗αIIbβ3的IgG1抑制性单克隆抗体)存在下引起内在血小板活化的可能机制,检查信号级联、鼠尾出血时间和免疫性血小板减少。

主要发现

  • TMV-7具有识别αIIbβ3的αIIb β螺旋桨结构域的结合基序,不同于TMV-2。
  • TMV-7既不使血小板致敏以结合配体,也不引起αIIbβ3构象改变(用配体诱导结合位点单克隆抗体AP5鉴定)。
  • 与依替巴肽和TMV-2不同,TMV-7与AP2共处理不诱导FcγRIIa介导的血小板聚集和下游活化级联。
  • TMV-2和TMV-7均有效预防体内闭塞性血栓。
  • 依替巴肽和TMV-2均引起FcγRIIa介导的严重血小板减少、延长体内鼠尾出血时间并抑制人全血凝血指标,而TMV-7不损害止血能力。

临床怎么用

  • 作者认为TMV-7可能作为具有更好安全性的治疗药物提供优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials FcγRIIa-mediated thrombocytopenia is associated with drug-dependent antibodies (DDAbs). We investigated the correlation between αIIb β3 binding epitopes and induction of DDAbs. An FcγRIIa-transgenic mouse model was used to evaluate thrombocytopenia among anti-thrombotics. An antithrombotic with binding motif toward αIIb β-propeller domain has less bleeding tendency. SUMMARY: Background Thrombocytopenia, a common side effect of Arg-Gly-Asp-mimetic antiplatelet drugs, is associated with drug-dependent antibodies (DDAbs) that recognize conformation-altered integrin αIIb β3 . Objective To explore the correlation between αIIb β3 binding epitopes and induction of DDAb binding to conformation-altered αIIb β3 , we examined whether two purified disintegrins, TMV-2 and TMV-7, with distinct binding motifs have different effects on induction of αIIb β3 conformational change and platelet aggregation in the presence of AP2, an IgG1 inhibitory mAb raised against αIIb β3 . Methods We investigated the possible mechanisms of intrinsic platelet activation of TMV-2 and TMV-7 in the presence of AP2 by examining the signal cascade, tail bleeding time and immune thrombocytopenia in Fc receptor γ-chain IIa (FcγRIIa) transgenic mice. Results TMV-7 has a binding motif that recognizes the αIIb β-propeller domain of αIIb β3 , unlike that of TMV-2. TMV-7 neither primed the platelets to bind ligand, nor caused a conformational change of αIIb β3 as identified with the ligand-induced binding site mAb AP5. In contrast to eptifibatide and TMV-2, cotreatment of TMV-7 with AP2 did not induce FcγRIIa-mediated platelet aggregation and the downstream activation cascade. Both TMV-2 and TMV-7 efficaciously prevented occlusive thrombosis in vivo. Notably, both eptifibatide and TMV-2 caused severe thrombocytopenia mediated by FcγRIIa, prolonged tail bleeding time in vivo, and repressed human whole blood coagulation indexes, whereas TMV-7 did not impair hemostatic capacity. Conclusions TMV-7 shows antiplatelet and antithrombotic activities resulting from a mechanism different from that of all other tested αIIb β3 antagonists, and may offer advantages as a therapeutic agent with a better safety profile.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kuo YJ, Chen YR, Hsu CC, et al. An αIIb β3 antagonist prevents thrombosis without causing Fc receptor γ-chain IIa-mediated thrombocytopenia. J Thromb Haemost. 2017. PMID: 28815933. doi:10.1111/jth.13803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。